TLX NASDAQ
Telix Pharmaceuticals Limited
1W: -7.9%
1M: -7.9%
3M: -13.2%
YTD: +38.5%
1Y: +3.7%
$10.55
-0.17 (-1.59%)
Weekly Expected Move ±10.7%
$8
$9
$11
$12
$13
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$1.2B
+53.9% ▲
5Y CAGR: +197.0%
Gross Profit
$640M
+25.6% ▲
Operating Income
$27M
-67.6% ▼
Net Income
-$11M
-121.4% ▼
EPS (Diluted)
$-0.03
-122.6% ▼
EBITDA
$80M
-18.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $8M | $160M | $503M | $783M | $1.2B |
| YoY Growth | +45.7% | +2007.6% | +213.9% | +55.8% | +53.9% |
| Cost of Revenue | $37M | $131M | $188M | $274M | $565M |
| Gross Profit | -$30M | $29M | $314M | $510M | $640M |
| Gross Margin | -391.9% | 18.3% | 62.6% | 65.1% | 53.1% |
| R&D Expenses | $34M | $58M | $129M | $121M | $257M |
| SG&A Expenses | $47M | $87M | $134M | $207M | $357M |
| Operating Expenses | $81M | $103M | $263M | $428M | $614M |
| Operating Income | -$81M | -$92M | $52M | $82M | $27M |
| Operating Margin | -1069.6% | -57.4% | 10.3% | 10.5% | 2.2% |
| Interest Expense | $189K | $406K | $14M | $21M | $55M |
| Income Before Tax | -$99M | -$99M | $3M | $56M | -$8M |
| Tax Expense | -$19M | $5M | -$2M | $6M | $3M |
| Net Income | -$81M | -$104M | $5M | $50M | -$11M |
| Net Margin | -1059.9% | -65.0% | 1.0% | 6.4% | -0.9% |
| EPS (Diluted) | $-0.29 | $-0.34 | $0.02 | $0.14 | $-0.03 |
| EBITDA | -$70M | -$93M | $23M | $98M | $80M |
| Shares Outstanding | 282M | 311M | 324M | 345M | 338M |